The study is intended to assess the safety and efficacy of perioperative treatment with
Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet
chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab
deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy
in participants with resectable, early-stage non-small cell lung cancer.